A $2.8T Opportunity?

Key Concepts

• Atherosclerotic Disease: A condition characterized by plaque buildup in the arteries, increasing the risk of cardiovascular events.
• Guideline Goals for Lipid Levels: Recommended targets for cholesterol and other fats in the blood, aimed at reducing cardiovascular risk.
• Total Addressable Market (TAM): The total market demand for a product or service.
• In Vivo Gene Editing: Gene editing performed directly within the body.
• Lipitor (Atorvastatin): A highly successful statin medication used to lower cholesterol.
• Value-Based Pricing: Setting prices based on the perceived value of a treatment to patients and healthcare systems.

Cardiovascular Disease Market Opportunity & In Vivo Gene Editing Potential

The speaker highlights a significant unmet need and substantial market opportunity within the treatment of atherosclerotic disease. Currently, 26 million individuals in the US suffer from this condition, characterized by plaque buildup in arteries and a heightened risk of events like heart attacks. Despite two-thirds of these patients having access to healthcare, approximately 17 million are not achieving guideline-recommended lipid levels. This represents a critical gap in care.

Total Addressable Market (TAM) Calculation

This unmet need translates into a massive Total Addressable Market (TAM) for effective treatments. The speaker calculates this TAM by multiplying the 17 million patients not meeting lipid goals by a value-based price of $165,000 per patient. This yields a TAM of $2.8 trillion – a figure described as “really large.” The $165,000 price point is presented as a value-based price, implying it reflects the potential health and economic benefits of effectively treating atherosclerotic disease.

Benchmarking Against Lipitor’s Success

To contextualize the $2.8 trillion TAM, the speaker draws a comparison to Lipitor (atorvastatin), a blockbuster statin medication. Over a 20-year period, Lipitor generated cumulative sales of “a little less than a quarter trillion” dollars. The speaker argues that an in vivo gene editing treatment capturing just 8% (or 1/12th) of the $2.8 trillion TAM would equal Lipitor’s blockbuster success. This demonstrates the potential scale of opportunity for companies like CRISPR Therapeutics developing in vivo gene editing therapies.

Implications for In Vivo Gene Editing

The speaker emphasizes that atherosclerotic disease is just one indication where in vivo gene editing could have a transformative impact. This example serves to illustrate the broader potential of this technology across various disease areas. The speaker states, “I think that’s really exciting,” underscoring the enthusiasm surrounding the possibilities of in vivo gene editing.

Logical Flow & Synthesis

The presentation logically progresses from identifying a large, underserved patient population (atherosclerotic disease) to quantifying the economic opportunity (TAM) and then benchmarking that opportunity against a proven pharmaceutical success (Lipitor). This comparison effectively illustrates the potential return on investment for in vivo gene editing therapies. The core takeaway is that in vivo gene editing holds the potential to address significant unmet medical needs and generate substantial revenue, making it a compelling area for investment and development.